Ampersand-backed Alliance Pharma to acquire LGC’s Drug Development Solutions Business (“DDS”) and welcomes KKR as joint shareholder

Malvern, PA, Cambridge, UK, and Sandwich, UK, May 17, 2022 – Alliance Pharma, a US-based Bioanalytical CRO and an Ampersand portfolio company, has agreed to acquire DDS, a UK-based Bioanalytical Business Unit of LGC. KKR will become an equal shareholder in the combined business alongside Ampersand Capital Partners.